All In Biotech

Drug Trial Radar · NCT06836232

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Zomagen Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period Cohort C will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period

Conditions

  • Recurrent Pericarditis

Interventions

  • VTX2735Drug

    Dose A, Daily

  • VTX2735Drug

    Dose B, Daily

  • VTX2735Drug

    Dose C, Daily

  • VTX2735Drug

    Dose D, Daily

  • VTX2735Drug

    Dose E, Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of VTX2735Time frame: Day 1 of treatment period through study completion, up to 26 weeks

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Site Location #840023

    La Jolla, California · Recruiting

  • Local Site #840014

    Orange, California · Recruiting

  • Local Site #840016

    Saint Augustine, Florida · Recruiting

  • Local Site #840008

    Chicago, Illinois · Recruiting

  • Local Site #840010

    Boston, Massachusetts · Recruiting

  • Local Site #840005

    Rochester, Minnesota · Recruiting

  • Local Site #840020

    New York, New York · Recruiting

  • Local Site #840017

    Cleveland, Ohio · Recruiting

  • Local Site #840019

    Houston, Texas · Recruiting

  • Local Site #840001

    Houston, Texas · Recruiting

  • Local Site #840013

    Salt Lake City, Utah · Recruiting

  • Local Site #840022

    Burlington, Vermont · Recruiting

  • Local Site #840004

    Richmond, Virginia · Recruiting

  • Local Site #840018

    Richmond, Virginia · Recruiting

  • Local Site #840021

    Seattle, Washington · Recruiting

  • Local Site #056001

    Ghent, Belgium · Recruiting

  • Local Site #056002

    Leuven, Belgium · Recruiting

  • Local Site #840102

    Montreal, Canada · Not yet recruiting

  • Local Site #840101

    Ottawa, Canada · Recruiting

  • Local Site #300001

    Athens, Greece · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.